Miller Industries's 15min chart indicates Bollinger Bands Narrowing and KDJ Death Cross.

Based on Miller Industries' 15-minute chart, a Bollinger Bands Narrowing signal has been triggered, accompanied by a KDJ Death Cross at 09/17/2025 15:00. This indicates a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, which may lead to further decreases in stock price.

X4 Pharmaceuticals (NASDAQ: XFOR), a clinical-stage biopharmaceutical company pioneering oral therapies targeting the CXCR4 pathway to treat rare immunodeficiency disorders, has announced a significant restructuring of its business operations aimed at driving long-term value creation. The restructuring, which includes a 50% workforce reduction, is expected to generate $13 million in annual cost savings X4 Pharmaceuticals Inc Stock Price, News & Analysis^[1].

Key management changes have been implemented as part of the restructuring. John Volpone has been appointed as COO while retaining his President role, and Dr. Adam Craig (Executive Chairman) will oversee clinical development. Several executives, including the Chief Legal Officer, former COO, Chief Commercial Officer, and Chief Medical Officer, have departed the company X4 Pharmaceuticals Inc Stock Price, News & Analysis^[1].

The restructuring is part of X4's strategic focus on advancing its 4WARD Phase 3 trial in chronic neutropenia patients. The trial, which is currently ongoing, is expected to complete enrollment in Q3/Q4 2025 and will provide top-line data in late 2026 .

In addition to the restructuring, X4 Pharmaceuticals has announced significant inducement grants to three new executive officers under its 2019 Inducement Plan. The grants include stock options for 12.7 million shares issued on August 12, 2025, and an additional 1.4 million shares on August 14, 2025. The options feature varying vesting schedules over 18-36 months, subject to performance conditions and continued employment .

The company has also successfully closed an upsized $85 million private placement, exceeding the initially announced $60 million offering. The financing includes 11,040,776 shares of common stock and pre-funded warrants to purchase 48,852,772 shares. The proceeds will support the continued development of mavorixafor for potential approval in chronic neutropenia and its commercialization in WHIM syndrome .

X4 Pharmaceuticals reported Q1 2025 financial results, with net revenue of $28.8 million, including $27.9 million from the Norgine agreement and $0.9 million from XOLREMDI product sales. The company ended Q1 with $87.7 million in cash, sufficient to fund operations into 1H 2026 .